SYSVASC
Systems Biology to Identify Molecular Targets for Vascular Disease Treatment
| Coordinatore | Medizinische Universitaet Graz
Organization address
address: AUENBRUGGERPLATZ 2 contact info |
| Nazionalità Coordinatore | Austria [AT] |
| Sito del progetto | http://www.sysvasc.eu/ |
| Totale costo | 8˙334˙864 € |
| EC contributo | 5˙976˙413 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2014 |
| Periodo (anno-mese-giorno) | 2014-02-01 - 2018-01-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
Medizinische Universitaet Graz
Organization address
address: AUENBRUGGERPLATZ 2 contact info |
AT (GRAZ) | coordinator | 871˙840.00 |
| 2 |
MOSAIQUES DIAGNOSTICS GMBH
Organization address
address: Mellendorfer Strasse 7-9 contact info |
DE (HANNOVER) | participant | 733˙600.00 |
| 3 |
UNIVERSITY OF GLASGOW
Organization address
address: University Avenue contact info |
UK (GLASGOW) | participant | 724˙166.00 |
| 4 |
SWISS INSTITUTE OF BIOINFORMATICS
Organization address
address: Rue Michel Servet 1 contact info |
CH (GENEVE) | participant | 444˙080.00 |
| 5 |
HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Organization address
address: Ingolstaedter Landstrasse 1 contact info |
DE (MUENCHEN) | participant | 400˙407.00 |
| 6 |
UNIVERSITY OF PLYMOUTH
Organization address
address: DRAKE CIRCUS contact info |
UK (PLYMOUTH) | participant | 399˙648.00 |
| 7 |
BIOCRATES LIFE SCIENCES AG
Organization address
address: EDUARD BODEM GASSE 8 1 STOCK contact info |
AT (Innsbruck) | participant | 382˙130.00 |
| 8 |
EAGLE GENOMICS LIMITED
Organization address
address: BABRAHAM RESEARCH CAMPUS BABRAHAM HALL contact info |
UK (BABRAHAM CAMBRIDGESHIRE) | participant | 373˙290.00 |
| 9 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 328˙560.00 |
| 10 |
THE UNIVERSITY OF MANCHESTER
Organization address
address: OXFORD ROAD contact info |
UK (MANCHESTER) | participant | 278˙660.00 |
| 11 |
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Organization address
address: BELFIELD contact info |
IE (DUBLIN) | participant | 260˙324.00 |
| 12 |
ServiceXS BV
Organization address
address: Plesmanlaan 1.d contact info |
NL (Leiden) | participant | 253˙800.00 |
| 13 |
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Organization address
address: GESCHWISTER-SCHOLL-PLATZ contact info |
DE (TUEBINGEN) | participant | 239˙564.00 |
| 14 |
"BIOMEDICAL RESEARCH FOUNDATION, ACADEMY OF ATHENS"
Organization address
address: Soranou Efesiou 4 contact info |
EL (ATHENS) | participant | 182˙160.00 |
| 15 |
BIOLUTION GMBH
Organization address
address: Karl-Farkas-Gasse 22 contact info |
AT (WIEN) | participant | 76˙184.00 |
| 16 |
UNIVERSITY OF BRITISH COLUMBIA
Organization address
address: AGRONOMY ROAD 102-6190 contact info |
CA (VANCOUVER) | participant | 28˙000.00 |
| 17 |
BAKER IDI HEART AND DIABETES INSTITUTE HOLDINGS LIMITED
Organization address
address: COMMERCIAL ROAD 75 VICTORIA contact info |
AU (MELBOURNE) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Asymptomatic vascular damage accumulates for years before patients are identified and subjected to therapeutic measures. The limited knowledge on early vascular disease pathophysiology is reflected in the lack of therapeutic options. SysVasc aims to overcome this limitation by mounting a comprehensive systems medicine approach to elucidate pathological mechanisms, which will yield molecular targets for therapeutic intervention. The consortium is based on established multidisciplinary European research networks, including specialists in pre-clinical and clinical research, omics technologies, and systems biology from research intensive SMEs and academia; partners synergistically provide access to an extensive number of selected population-based cohorts and associated datasets, cutting edge modeling and simulation methods, and established cardiovascular disease (CVD) animal models and patient cohorts. The coordinated application of these tools and know-how will identify pathophysiological mechanisms and key molecules responsible for onset and progression of CVD and validate their potential to serve as molecular targets for therapeutic intervention. To this end, the consortium will also use unique resources to evaluate molecular homology between the available model systems and human disease, which will yield reliable essential preclinical research tools to explore proof of concepts for therapeutic intervention studies and ultimately translate relevant results into novel therapeutic approaches. Collectively, SysVasc will identify and validate novel biology-driven key molecular targets for CVD treatment. Major scientific, societal and economic impact is expected including, but not limited to, providing a valuable resource to further CVD research, and enhance competitiveness of participating SMEs and European health industry in general by translating knowledge into “innovative services” in therapeutic target and drug research.'
Altri progetti dello stesso programma (FP7-HEALTH)
PREPOBEDIA (2008)
NOVEL PREP1-DEPENDENT TRANSCRIPTIONAL NETWORKS IN THE CONTROL OF INSULIN SENSITIVITY
Read More